Drugs / NKTR-255
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials · 1 met primary | ||||||
| Phase 1 | NCT05676749 | Feb 2024 → Dec 2025 | non-small cell lung carcinoma | AbelZeta Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05359211 | Dec 2022 → Sep 2025 | primary mediastinal large B-cell lymphoma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT04136756 | Oct 2019 → Apr 2023 | non-Hodgkin lymphoma, plasma cell myeloma | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03233854 | Sep 2017 → Jun 2023 overdue | B-cell acute lymphoblastic leukemia | Stanford University | Active not recruiting | Met primary |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04616196 | Oct 2020 → Mar 2023 | colorectal cancer, head and neck squamous cell carcinoma | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05632809 | Jan 2023 → Dec 2027 expected | lung cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05327530 | Aug 2022 → Jun 2025 overdue | urothelial carcinoma | EMD Serono Research & Development Institute, Inc. | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05664217 | Dec 2022 → May 2024 | diffuse large B-cell lymphoma | Nektar Therapeutics | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 18
| Date | Issuer | Release |
|---|---|---|
| 2024-12-07 | Nektar Therapeutics | Results Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting nektar.com ↗
Nektar Therapeutics (Nasdaq: NKTR) today announced results of its Phase 2 proof-of-concept study evaluating NKTR-255 as an adjuvant treatment to enhance complete response rate (CRR) and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory (R/R) Large B-cell Lymphoma (LBCL) at the 66 th ASH Annual Meeting and Exposition in San Diego, California . |
| 2024-11-07 | Nektar Therapeutics | Results Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting nektar.com ↗
The results from the preplanned interim analysis from the REStoring lymphoCytes Using NKTR-255 after chemoradiothErapy in solid tumors (RESCUE) trial suggest that NKTR-255 effectively reversed radiation induced lymphopenia in patients with locally advanced NSCLC receiving consolidation therapy with durvalumab. |
| 2024-10-17 | Nektar Therapeutics | Results Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia nektar.com ↗
The data published in Blood showed favorable efficacy with eight out of nine patients (89%) whom successfully received CAR19-22 followed by NKTR-255 achieving measurable residual disease (MRD) negative remission. |
| 2023-12-11 | Nektar Therapeutics | Results Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting nektar.com ↗
Nektar Therapeutics (NASDAQ:NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College presented a poster highlighting new preclinical data on NKTR-255 at the 65 th American Society of Hematology (ASH) Annual Meeting demonstrating that NKTR-255 significantly enhanced the cytotoxicity of expanded Natural Killer (NK) cells when combined with obinutuzumab against rituximab-resistant BL cells and significantly improved the survival of mice xenografted with Raji-4RH compared to controls. |
| 2022-12-12 | Nektar Therapeutics | Results Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting nektar.com ↗ |
| 2022-11-09 | Nektar Therapeutics | Results Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy nektar.com ↗
The data from this publication demonstrate that NKTR-255 not only enhanced in vivo proliferation and accumulation of T and NK cells in non-human primates, but also demonstrated enhanced in vivo antitumor efficacy of human CD19 CAR-T in lymphoma-bearing immunodeficient mice. |
| 2022-08-16 | Nektar Therapeutics | Results Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK Cell Function in Multiple Myeloma nektar.com ↗
The published data demonstrate that NKTR-255 not only enhances antitumor responses of human NK cells against MM target cells, but also increases ex vivo expression of NK activating receptors and adhesion molecules. |
| 2022-04-23 | Nektar Therapeutics | Results Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® nektar.com ↗
NKTR-255 enhances expression of NK cell-activating receptors, stimulates NK cell proliferation and sustains NK cell expansion |
| 2021-12-13 | Nektar Therapeutics | Results Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of Hematology (ASH) Annual Meeting nektar.com ↗
Initial clinical results from the Phase 1 study of NKTR-255 in patients with relapsed/refractory (R/R) hematologic malignancies were presented by Nina Shah , M.D., Associate Professor, Department of Medicine , at the University of California San Francisco on Monday, December 13 th . |
| 2021-11-12 | Nektar Therapeutics | Results Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting nektar.com ↗ |
| 2021-05-18 | Nektar Therapeutics | Results Nektar Therapeutics Announces its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC) nektar.com ↗
The published data demonstrate that NKTR-255 retains the full spectrum of IL-15 biology but with improved pharmacologic properties and anti-tumor activity versus other rhIL-15 agonists. |
| 2020-12-07 | Nektar Therapeutics | Results Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting nektar.com ↗
In our studies, we found the novel IL-15 receptor agonist, NKTR-255, was effective in reverting the inhibitory status observed in NK cells from MM patients, leading to enhanced direct NK cytotoxicity against several MM c |
| 2020-11-11 | Nektar Therapeutics | Results Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting nektar.com ↗
New clinical results were presented for bempegaldesleukin (BEMPEG; NKTR-214), NKTR-262 and NKTR-255. |
| 2019-12-09 | Nektar Therapeutics | Results Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting nektar.com ↗
Treatment with NKTR-255 enhanced the number and function of both NK and CD8+ effector memory T cell populations in peripheral blood from healthy donors and MM patients in a dose dependent manner. |
| 2019-11-09 | Nektar Therapeutics | Results Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting nektar.com ↗
NKTR-255 treatment of NK cells enhanced activity of antibody-dependent cellular cytotoxicity (ADCC) against tumor cells in vitro, and in vivo efficacy of ADCC-inducing antibodies in human solid tumor xenograft models. |
| 2019-04-02 | Nektar Therapeutics | Results Nektar Therapeutics Presents Preclinical Data on its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019 nektar.com ↗
NKTR-255 showed a dose-dependent effect on the proliferation and activation of natural killer (NK) cells. |
| 2018-11-09 | Nektar Therapeutics | Results Nektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting nektar.com ↗
NKTR-255 demonstrated powerful immune stimulation of NK cells with dose-dependent effect in the proliferation and activation of NK cells and enhanced anti-metastatic activity in mouse lung metastasis models. |
| 2017-04-04 | Nektar Therapeutics | Results Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting nektar.com ↗
The presentations featured new preclinical data on NKTR-214, the Company's immuno-stimulatory CD122-biased agonist, as well as on NKTR-255, the Company's IL-15 therapeutic candidate. |
All press releases naming this drug 22 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKTR-255 | “NKTR-255” NCT05676749 ↗ |
| Action | Activate | “NKTR-255 is an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer.” NCT03233854 ↗ |
| Modality | Protein / enzyme biologic | “novel recombinant polymer-conjugated IL15 receptor agonist (NKTR-255)” PMID 38968138 ↗ Oct 2024 |
| Route | Intravenous | “NKTR-255 administered by IV infusion every 21 or 28 days to establish safety and tolerability” NCT04136756 ↗ |